David S H Bell Mb

List of Publications by Year
in descending order

74	4,082	304743 22	114465 63
papers	citations	h-index	g-index

75	75	75	5551
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a TypeÂ1 Diabetic Patient. Diabetes Therapy, 2022, , 1.	2.5	0
2	Metforminâ€induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1423-1428.	4.4	22
3	Diabetogenic effects of cardioprotective drugs. Diabetes, Obesity and Metabolism, 2021, 23, 877-885.	4.4	13
4	Development of Exogenous Insulin Antibody Syndrome in a Patient with Newly Diagnosed TypeÂ1 Diabetes Successfully Treated with Oral Immunosuppressive Monotherapy. Diabetes Therapy, 2021, 12, 2795-2799.	2.5	5
5	Alcohol Consumption as a Causator and/or an Accelerator of Neuropathy in People With Diabetes Is Regularly Overlooked. Diabetes Therapy, 2021, 12, 2631-2634.	2.5	2
6	Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant?. Diabetes Therapy, 2021, 12, 3025-3035.	2.5	9
7	Why Do Falls and Lower Limb Fractures Occur More Frequently in the Diabetic Patient and How Can They Be Prevented?. Diabetes Therapy, 2020, 11, 1687-1694.	2.5	6
8	Stroke in the patient with diabetes (Part 2) â€“ Prevention and the effects of glucose lowering therapies. Diabetes Research and Clinical Practice, 2020, 164, 108199.	2.8	5
9	Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin. Diabetes Therapy, 2020, 11, 1175-1177.	2.5	0
10	Stroke in the patient with diabetes (part 1) â€“ Epidemiology, etiology, therapy and prognosis. Diabetes Research and Clinical Practice, 2020, 164, 108193.	2.8	14
11	Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of antiâ€diabetic therapies. Diabetes, Obesity and Metabolism, 2019, 21, 210-217.	4.4	95
12	Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucoseâ€lowering medications. Diabetes, Obesity and Metabolism, 2019, 21, 1277-1290.	4.4	64
13	Correlation between serum uric acid and diabetic peripheral neuropathy â€“ association rather than causation. Journal of the Neurological Sciences, 2018, 390, 208.	0.6	2
14	Finally, after 56 years of type 1 diabetes: a regimen that works. Postgraduate Medicine, 2018, 130, 409-410.	2.0	2
15	Re: Diabetic Ketoacidosis in Patients with Type 2 Diabetes On Sglt-2 Inhibitors: an Ongoing Concern. Endocrine Practice, 2018, 24, 126.	2.1	2
16	Should we still be utilizing warfarin in the type 2 diabetic patient?. Diabetes, Obesity and Metabolism, 2018, 20, 2327-2329.	4.4	4
17	Increase in glycated haemoglobin concentrations after unwarranted prescription changes. Diabetes, Obesity and Metabolism, 2018, 20, 2510-2511.	4.4	2
18	Glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose coâ€transporterâ€2 inhibitors: <scp>S</scp>equential or simultaneous start?. Diabetes, Obesity and Metabolism, 2017, 19, 909-911.	4.4	12

#	Article	IF	Citations
19	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017, 23, 1-87.	2.1	766
20	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Progress in Cardiovascular Diseases, 2017, 60, 422-434.	3.1	87
21	Aspirin in the prevention of cardiovascular events in patients with diabetes. Postgraduate Medicine, 2016, 128, 180-190.	2.0	5
22	Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient. Case Reports in Endocrinology, 2015, 2015, 1-4.	0.4	7
23	Reply. American Journal of Cardiology, 2015, 115, 852-853.	1.6	0
24	Riceabetes: is the association of type 2 diabetes with rice intake due to a high carbohydrate intake or due to exposure to excess inorganic arsenic?. Postgraduate Medicine, 2015, 127, 781-782.	2.0	6
25	Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR. Postgraduate Medicine, 2012, 124, 121-135.	2.0	8
26	Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. American Journal of Cardiology, 2012, 110, 826-833.	1.6	141
27	Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings, 2011, 86, 128-138.	3.0	50
28	Lowering the Triglyceride/High-Density Lipoprotein Cholesterol and its Association With the Beneficial Impact of Pioglitazone on Coronary Atherosclerosis in the PERISCOPE Study Is Likely Due to Lowering Insulin Resistance. Journal of the American College of Cardiology, 2011, 58, 778.	2.8	4
29	Protean Manifestations of Vitamin D Deficiency, Part 3. Southern Medical Journal, 2011, 104, 340-344.	0.7	9
30	Protean Manifestations of Vitamin D Deficiency, Part 1. Southern Medical Journal, 2011, 104, 331-334.	0.7	15
31	Metformin-Induced Vitamin B12 Deficiency Presenting as a Peripheral Neuropathy. Southern Medical Journal, 2010, 103, 265-267.	0.7	95
32	Resolution of Statin-Induced Myalgias by Correcting Vitamin D Deficiency. Southern Medical Journal, 2010, 103, 690-692.	0.7	31
33	The Association of Obesity, Metabolic Syndrome, Diabetes, and Cardiovascular Disease with Nonalcoholic Fatty Liver Disease. Southern Medical Journal, 2009, 102, 991-992.	0.7	5
34	Metabolic syndrome and postoperative atrial fibrillation (POAF). European Heart Journal, 2009, 30, 1167-1168.	2.2	4
35	Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetologica, 2009, 46, 155-155.	2.5	0
36	Treatment of diabetic hypertension. Diabetes, Obesity and Metabolism, 2009, 11, 433-444.	4.4	16

#	Article	IF	Citations
37	Successful Utilization of Aliskiren, a Direct Renin Inhibitor in Bartter Syndrome. Southern Medical Journal, 2009, 102, 413-415.	0.7	2
38	Importance of Postprandial Glucose Levels in Type 2 Diabetes. Southern Medical Journal, 2009, 102, 553.	0.7	1
39	Hypertension and Diabetesâ€"A Toxic Combination. Endocrine Practice, 2008, 14, 1031-1039.	2.1	21
40	Peyronie Disease in Association with Carvedilol: A Case Report. Southern Medical Journal, 2008, 101, 1157-1158.	0.7	5
41	Diabetes: A Cardiac Condition Manifesting as Hyperglycemia. Endocrine Practice, 2008, 14, 924-932.	2.1	19
42	Postprandial Dysmetabolism: the Missing Link Between Diabetes and Cardiovascular Events?. Endocrine Practice, 2008, 14, 112-124.	2.1	72
43	Triple oral therapy for type 2 diabetes. Diabetes Research and Clinical Practice, 2007, 78, 313-315.	2.8	8
44	Insulin Therapy in Diabetes Mellitus. Drugs, 2007, 67, 1813-1827.	10.9	20
45	Heart Failure in the Diabetic Patient. Cardiology Clinics, 2007, 25, 523-538.	2.2	13
46	Postprandial Hyperglycemia/Hyperlipidemia (Postprandial Dysmetabolism) Is a Cardiovascular Risk Factor. American Journal of Cardiology, 2007, 100, 899-904.	1.6	452
47	The Case for Combination Therapy as First-Line Treatment for the Type 2 Diabetic Patient. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 131-137.	1.8	10
48	The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Current Medical Research and Opinion, 2006, 22, 287-296.	1.9	66
49	Treatment of type 2 diabetes. Postgraduate Medicine, 2006, 119, 15-20.	2.0	1
50	Treatment of type 2 diabetes. Postgraduate Medicine, 2006, 119, 8-14.	2.0	4
51	Do sulfonylurea drugs increase the risk of cardiac events?. Cmaj, 2006, 174, 185-186.	2.0	54
52	Strategies to prevent type 2 diabetes. Current Medical Research and Opinion, 2005, 21, 1107-1114.	1.9	40
53	Differential Effects of Î²-Blockers on Albuminuria in Patients With Type 2 Diabetes. Hypertension, 2005, 46, 1309-1315.	2.7	76
54	Insulin as Initial Therapy for Type 2 Diabetes is Not in the Patientâ€™S Best Interest. Endocrine Practice, 2004, 10, 208-212.	2.1	5

#	Article	IF	Citations
55	Effect of Rosiglitazone Versus Insulin on the Pancreatic Î²-Cell Function of Subjects With Type 2 Diabetes. Diabetes Care, 2004, 27, 2585-2589.	8.6	87
56	Efficacy of Conversion From Bedtime NPH Insulin Injection to Once- or Twice-Daily Injections of Insulin Glargine in Type 1 Diabetic Patients Using Basal/Bolus Therapy. Diabetes Care, 2004, 27, 632-633.	8.6	75
57	Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2227.	7.4	710
58	Management of Type 2 Diabetes With Thiazolidinediones. , 2004, 14, 293-299.		7
59	The Role of C-Peptide Levels in Screening for Latent Autoimmune Diabetes in Adults. American Journal of Therapeutics, 2004, 11, 308-311.	0.9	23
60	Advances in diabetes for the millennium: the heart and diabetes. MedGenMed: Medscape General Medicine, 2004, 6, 7.	0.2	0
61	Î²-Cell rejuvenation with thiazolidinediones. American Journal of Medicine, 2003, 115, 20-23.	1.5	60
62	Heart Failure. Diabetes Care, 2003, 26, 2433-2441.	8.6	387
63	Use of Beta Blockers in the Patient With Diabetes. , 2003, 13, 116-123.		17
64	Why I Initiate Therapy with Two Insulin Sensitizers in Patients with Type 2 Diabetes. Endocrine Practice, 2003, 9, 98-100.	2.1	9
65	Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus. Postgraduate Medicine, 2003, Spec No, 35-44.	2.0	3
66	Long-Term Efficacy of Triple Oral Therapy for Type 2 Diabetes Mellitus. Endocrine Practice, 2002, 8, 271-275.	2.1	50
67	Current status of diabetes treatment. Southern Medical Journal, 2002, 95, 24-9.	0.7	3
68	Chronic complications of diabetes. Southern Medical Journal, 2002, 95, 30-4.	0.7	1
69	Drugs for cardiovascular risk reduction in the diabetic patient. Current Diabetes Reports, 2001, 1, 133-139.	4.2	5
70	Dealing with diabetic nephropathy. Postgraduate Medicine, 1999, 105, 83-94.	2.0	10
71	Diabetic ketoacidosis. Postgraduate Medicine, 1997, 101, 193-204.	2.0	15
72	Lower limb problems in diabetic patients. Postgraduate Medicine, 1991, 89, 237-244.	2.0	8

#	Article	IF	Citations
73	Dosage Accuracy of Self-mixed vs Premixed Insulin. Archives of Internal Medicine, 1991, 151, 2265.	3.8	32
74	Peripheral and autonomic syndromes. Postgraduate Medicine, 1982, 71, 50-67.	2.0	19